SCHEMBL6653655

SCHEMBL6653655

CCCCCCCCCNC(=O)/C=C/c1ccc(O)cc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 3/20 0.62
▸ HTR1A P08908 2/20 0.62
▸ HTR2C P28335 2/20 0.62
▸ HTR2A P28223 1/20 0.62
▸ SLC6A4 P31645 1/20 0.62
▸ HTR7 P34969 1/20 0.62
▸ HTR6 P50406 1/20 0.62
▸ LY96 Q9Y6Y9 1/20 0.60
▸ PTGS2 P35354 2/20 0.56
▸ PTGS1 P23219 1/20 0.56
▸ TYR P14679 1/20 0.55
▸ PELI1 Q96FA3 1/20 0.55
▸ HPGD P15428 1/20 0.54
▸ EGFR P00533 1/20 0.53
▸ CTSL P07711 1/20 0.53
▸ CTSB P07858 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ CNR2 P34972 1/20 0.53
▸ BACE1 P56817 2/20 0.52
▸ MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6653659 1.00 APP (0.62) APPHTR1AHTR2CHTR2ASLC6A4
SCHEMBL8756981 0.86 APP (0.62) APPHTR1AHTR2CHTR2ASLC6A4
SCHEMBL8756992 0.86 APP (0.62) APPHTR1AHTR2CHTR2ASLC6A4
SCHEMBL8756987 0.86 APP (0.62) APPHTR1AHTR2CHTR2ASLC6A4
SCHEMBL6659156 0.84 EGFR (0.56) APPHTR1AHTR2CHTR2ASLC6A4
SCHEMBL6659147 0.84 EGFR (0.56) APPHTR1AHTR2CHTR2ASLC6A4
SCHEMBL5755690 0.84 EGFR (0.64) HTR1AHTR2CHTR2ASLC6A4HTR7
SCHEMBL19358993 0.83 APP (0.64) APPHTR1AHTR2CHTR2ASLC6A4
SCHEMBL19369311 0.83 APP (0.64) APPHTR1AHTR2CHTR2ASLC6A4
Feruloylhexylamide SCHEMBL14638587 0.79 TYR (0.88) APPHTR1AHTR2CHTR2ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040254241-A1 Enzyme inhibitor; cognition activators KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-12-16 — — US disclosed
EP-1431280-A1 ARYL SULFAMATE DERIVATIVES Kyowa Hakko Kogyo Co., Ltd (JP) 2004-06-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254241-A1 Enzyme inhibitor; cognition activators SULT1A1, STS, CYP26A1 APP 2002/4885HTR1A 140/4885HTR2C 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback